WHITEHAWK THERAPEUTICS INC (WHWK)
Health Care · Oncology therapeutics / antibody-drug conjugates · NASDAQ
Clinical-stage oncology company developing next-generation antibody-drug conjugates (ADCs) targeting validated tumor antigens with advanced linker-payload technology.
What WHITEHAWK THERAPEUTICS INC does
Whitehawk Therapeutics is a clinical-stage oncology company focused on developing and commercializing next-generation antibody-drug conjugates (ADCs) using advanced linker-payload platforms. The company in-licensed a portfolio of three ADCs (HWK-007, HWK-016, HWK-206) from WuXi Biologics and Hangzhou DAC Biotechnology, each targeting distinct tumor antigens (PTK7, MUC16, SEZ6) in cancer indications including non-small cell lung cancer, ovarian cancer, endometrial cancer, small cell lung cancer, and neuroendocrine tumors. The company leverages deep experience in drug formulation, delivery technology, and oncology development, with Phase 1 trials already active for two lead candidates and data readouts expected in the first half of 2027.
Themes: ADC development / antibody-drug conjugates, Oncology / cancer therapeutics, Targeted cancer therapy, Clinical-stage therapeutics, Drug delivery technology
Fundamentals
- Price$4.73 as of 2026-08-21 close
- Market cap$270M as of 2026-08-21
- 1-year return+186.7% 2025-08-21 close $1.65 → 2026-08-21 close $4.73
- P/En/a negative earnings
- Net margin+99.4% as of 2026-08-24
- Gross margin+88.7% as of 2026-08-24
- ROE-79.6% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)-22.3% as of 2026-08-24
- Revenue CAGR (3y)-22.3% SEC XBRL
- Beta0.93 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How WHWK compares in its sector
- net profit margintop 10% 504 covered Health Care peers, as of 2026-08-24
- operating margintop 10% 504 covered Health Care peers, as of 2026-08-24
- gross margintop 25% 384 covered Health Care peers, as of 2026-08-24
- return on equitybottom 25% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRbottom 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Dividend coverage
Not assessed — last reported dividend predates the accounts. The most recent fiscal year in which WHWK reported a dividend payment is FY2021, while its reported financial statements run through FY2025. Coverage is therefore not assessed for the latest year — an FY2021 ratio would not describe WHWK today.
Coverage is derived from reported SEC EDGAR XBRL figures, comparing dividends paid against net income and free cash flow for the SAME fiscal year. It is not shown here because the latest fiscal year with a reported dividend payment (FY2021) is older than the latest year of reported financial statements (FY2025), so any ratio would describe an out-of-date year. Informational only — not financial advice.
How WHITEHAWK THERAPEUTICS INC looks technically
WHITEHAWK THERAPEUTICS INC (WHWK) is trading 40.1% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 192 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 14, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 60, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 3 trading days ago.
Trend
7
| Distance from the 200-day | it is trading 40.1% above its 200-day average, the long-term trend line — a longer-term uptrend | +40.1% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $4.20 | $4.20 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $3.38 | $3.38 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 11 calendar days ago — the swings before that are what the structure reading is measured on | 11 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 192 trading days ago — a "golden cross", a bullish long-term signal | 192 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 14, below the 25 that marks a real trend) | 14.3 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 60, neither overbought (above 70) nor oversold (below 30) | 60.4 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($3.98 to $5.00) — its "stochastic" reading is 74 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 73.5 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 16 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $5.50 | $5.50 |
|---|---|---|
| From the 52-week high | it is 13.9% below its 52-week high (its highest price of the past year) | -13.9% |
| Above the 52-week low | it is 201.3% above its 52-week low (its lowest price of the past year) | +201.3% |
| Below the 52-week high | it is 13.9% below its highest point of the past year | 13.9% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 3 trading days ago | 3 sessions |
| All-time high | its highest closing price on record is $78.00 (set on 2018-03-20) | $78.00 |
| Given back of the 52-week move | over the past year its closes ranged ($1.60 to $5.10), and it has given back only a small part of its rise from last year’s low — 11% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $2.83 to $2.94. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 10.6% |
| From the all-time high | it is 93.9% below its all-time high | -93.9% |
| Nearest price level | it is trading 3.1% below a resistance level at $4.88 — a price it turned at twice since 2026-07-01, most recently on 2026-08-10. Since 2024-08-21 it has 10 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +3.1% |
| All-time low | its lowest closing price on record is $1.21 (set on 2024-08-08) | $1.21 |
| Above the all-time low | it is 290.9% above its all-time low | +290.9% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 90% of the past ~6 months) | 90th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.2844 between its high and its low — about 6.0% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.2844 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $3.50 and $5.22 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $3.50 – $4.36 – $5.22 |
| Typical daily range (% of price) | its price moves about 6.0% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.0% |
| Stretch from the 200-day average | it is trading 4.8 daily ranges above its 200-day average price (40.1% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 4.8 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.53× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 1 session ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 1 session ago |
|---|---|---|
| Since a bearish engulfing | 9 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 9 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-08-21 0.8% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.8% |
|---|---|---|
| Gap filled | a 3.2% gap up opened on 2026-06-25 has been "filled" 40 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 40 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -2.87% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 18.6 percentage points (the stock gained 21.0% while the market gained 2.3%) | +18.6% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 6.9 percentage points (the stock gained 10.0% while the market gained 3.1%) | +6.9% |
| vs market, 6 months | over the past 6 months this stock beat the market by 44.0 percentage points (the stock gained 55.1% while the market gained 11.1%) | +44.0% |
| vs market, 12 months | over the past 12 months this stock beat the market by 166.2 percentage points (the stock gained 186.7% while the market gained 20.5%) | +166.2% |
Signal agreement
2
| Bullish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
|---|---|---|
| Bearish technical signals | 0 of the 9 technical signals we can compute for it are currently in a bearish state — these describe past price behaviour, not a forecast | 0 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 3.5% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thick, spanning 9.1% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | +3.5% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 16% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $4.07 — a volume-weighted average of daily closes over 150 sessions, not a true tick-by-tick VWAP. | +16.1% |
|---|---|---|
| Vs the average paid since it last reported | the price is 1% above the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $4.68 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | +1.0% |
Price levels it has turned at before
WHWK last closed at $4.73 on 2026-08-21. Since 2024-08-21 it has turned at 10 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $4.88 | Resistance | 3.1% above the last close | turned there twice · 2026-07-01 to 2026-08-10 |
| $3.78 | Support | 20.1% below the last close | turned there five times · 2025-01-08 to 2026-07-07 |
| $3.64 | Support | 23.1% below the last close | turned there three times · 2024-12-20 to 2026-07-16 |
| $2.92 | Support | 38.2% below the last close | turned there twice · 2025-01-14 to 2025-02-19 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Broke out to a new 20-day high · trendless / choppy (low ADX) · beating the market · Most volatile (6%+ typical daily range) · Trading above the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · breakout
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.88 mean, 1=Strong Buy…5=Strong Sell) — 6 analysts
- Mean price target$7.50 range $4.00 – $10.00
Analyst estimates, as of 2026-08-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for WHWK
- Consensus EPS estimate-$0.2467 next reporting period, as of 2026-08-18
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Early-stage development risk: all three lead ADC candidates are in Phase 1 trials with data not expected until H1 2027, carrying typical clinical trial and regulatory approval uncertainties","Revenue decline and operational transition: company divested legacy FYARRO business (generating $7.1M in 2025 vs. $26.0M in 2024), creating cash burn dependence on in-licensed ADC portfolio success","Dependence on collaboration partners: success relies on WuXi Biologics for manufacturing and development of in-licensed ADCs, with execution risk dependent on third-party partners"]
What changed in the latest 10-Q
AI-assisted comparison of WHWK's 10-Q filed 2026-05-07 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- In December 2024, we entered into an intellectual property license agreement (added specific timing to clarify when the agreement was entered into)
- IND applications for HWK-007 and HWK-016 were submitted in the fourth quarter of 2025 and FDA has cleared these applications
- Phase 1 trials for HWK-007 and HWK-016 are now actively recruiting
- Data readouts expected in the first half of 2027 for HWK-007 and HWK-016 trials
- HWK-206 intended for treatment of small cell lung cancer (SCLC) and neuroendocrine tumors (NETs)
- Company is described as 'clinical-stage oncology therapeutics company' instead of just 'oncology therapeutics company'
- Net product sales figures specified as 'for the three months ended March 31, 2026 and 2025, respectively'
- Removed:
- Reference to 'Mirati Therapeutics, Inc.' removed from the list of former agreements
- Language 'we anticipate submitting three investigational new drug applications with the U.S. Food and Drug Administration by mid-2026, starting with' changed to reflect actual submissions already made
- HWK-206 previously described as 'for the treatment of cancers of neuroendocrine origin' now specified as 'for the treatment of small cell lung cancer (SCLC) and neuroendocrine tumors (NETs)'
- Reference to 'nine months ended September 30, 2025' removed from net product sales discussion
- Language 'and, as a result, we no longer operate the FYARRO Business and KAKEN acquired the rights to the Aadi Bioscience, Inc. name and any related trademarks' appears truncated in newer version
- Reworded:
- Changed from 'We recently entered into' to 'In December 2024, we entered into' for License Agreement timing
- Changed from 'TOP1' to 'TOP1' (consistent spelling, older version used 'TOPO1')
- Changed from 'for the year ending December 31, 2024 filed with the SEC on March 28, 2025' to 'for the year ended December 31, 2025 filed with the SEC on March 12, 2026'
- Changed from 'We anticipate submitting three investigational new drug applications' with future tense to 'We submitted investigational new drug applications' with past tense for HWK-007 and HWK-016
- Changed from 'upcoming Phase 1 trials' to 'ongoing and upcoming Phase 1 trials'
- Notes:
- The newer filing appears to be for Q1 2026 (ended March 31, 2026) while the older filing is for Q3 2025 (ended September 30, 2025), representing different reporting periods
- Some text appears truncated at the end of the provided excerpt in the newer filing, potentially affecting completeness of comparison
Risk Factors
- Added:
- Newer filing (2026-05-07) adds: 'Please see the "Cautionary Statement Regarding Forward Looking Statements" section of this Quarterly Report for a discussion of some of the forward-looking statements that are qualified by these risk factors.'
- Newer filing (2026-05-07) adds: 'These disclosures reflect our beliefs and opinions as to factors that could materially and adversely affect our company and our securities in the future. References to past events are provided by way of example only and are not intended to be a complete listing or a representation as to whether or not such factors have occurred in the past or their likelihood of occurring in the future.'
- Newer filing (2026-05-07) adds new risk factor: 'We are currently dependent on single-source suppliers for our product candidates and their components, including Hangzhou DAC and WuXi Biologics.'
- Removed:
- Older filing (2025-11-06) states: 'These risks include, but are not limited to, the following:' - this specific phrase is removed in newer filing.
- Older filing (2025-11-06) references: 'Part II, Item 1A. "Risk Factors" in this Quarterly Report on Form 10-Q' - this cross-reference is removed in newer filing.
- Reworded:
- Risk factor description changed from 'We are a preclinical-stage biopharmaceutical company, have a limited operating history and have three preclinical products in development' (older, 2025-11-06) to 'We are a clinical-stage biopharmaceutical company, have a limited operating history and have two clinical and one preclinical products in development' (newer, 2026-05-07)
- Risk factor description changed from 'discovery, development and commercialization of a portfolio of three next generation antibody drug conjugates ("ADC Therapies")' (older, 2025-11-06) to 'discovery, development and commercialization of the ADC Therapies' (newer, 2026-05-07)
- Heading changed from 'We are a preclinical-stage biopharmaceutical company, have a limited operating history and had a single product approved for commercial sale that we have divested' (older, 2025-11-06) to 'We are a clinical-stage biopharmaceutical company, have a limited operating history and had a single product approved for commercial sale that we have divested' (newer, 2026-05-07)
- Opening text of detailed risk section changed from 'We are a preclinical-stage biopharmaceutical company with a limited operating history' (older, 2025-11-06) to 'We are a clinical-stage biopharmaceutical company with a limited operating history' (newer, 2026-05-07)
- Older filing (2025-11-06) states 'We contract with qualified third parties for the production of pre-clinical product supplies' whereas newer filing (2026-05-07) states 'We contract with qualified third parties for the production of preclinical and clinical product supplies'
- Notes:
- The newer filing text is truncated at the end of the Risk Factors section, so complete comparison of the detailed risk sections may not be fully assessable.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days.
- Last 180 days0 buys · 11 sells ($3M) — 3 selling insiders
Most recent open-market transaction: 2026-04-16. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about WHWK's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding WHWK as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 1,032,241
- Reported value $3,561,231
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 2 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
WHWK had 4,429,973 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
WHWK had 7.77% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 10.35 days to cover at the same settlement.
- Reported short interest (shares) 4,429,973
- Short interest (% of shares outstanding) 7.77%
- Prior settlement (shares) 4,179,811
- Reported change 5.99%
- Days to cover (reported) 10.35
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Seagen (SGEN)
- Pfizer (PFE)
- Genmab (GMAB)
- Astellas Pharma (ASPH)
- Gilead Sciences (GILD)
- ImmunoMedics (now Gilead subsidiary)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare WHWK vs…
WHITEHAWK THERAPEUTICS INC is found in…
WHWK ranks in…
Frequently asked questions
What does WHITEHAWK THERAPEUTICS INC (WHWK) do?
Whitehawk Therapeutics is a clinical-stage oncology company focused on developing and commercializing next-generation antibody-drug conjugates (ADCs) using advanced linker-payload platforms. The company in-licensed a portfolio of three ADCs (HWK-007, HWK-016, HWK-206) from WuXi Biologics and Hangzhou DAC Biotechnology, each targeting distinct tumor antigens (PTK7, MUC16, SEZ6) in cancer indications including non-small cell lung cancer, ovarian cancer, endometrial cancer, small cell lung cancer,…
What sector is WHITEHAWK THERAPEUTICS INC (WHWK) in?
WHITEHAWK THERAPEUTICS INC (WHWK) is classified in the Health Care sector. Its industry is Oncology therapeutics / antibody-drug conjugates. It trades on NASDAQ.
Who are WHITEHAWK THERAPEUTICS INC's (WHWK) competitors?
Notable peers of WHITEHAWK THERAPEUTICS INC (WHWK) include Seagen, Pfizer, Genmab, Astellas Pharma and Gilead Sciences. This peer set is informational only — not financial advice.
Is WHITEHAWK THERAPEUTICS INC (WHWK) overbought or oversold right now?
WHITEHAWK THERAPEUTICS INC (WHWK) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 60, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on WHWK come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.